ATLANTA, GA – – (ACCESSWIRE – November 15, 2022) – – Holzer & Holzer, LLC is investigating whether Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI) complied with federal securities laws. On November 15, 2022, Culper Research published a report alleging Treace Medical has driven its business through “aggressive reimbursement practices and deceptive [direct to consumer] marketing.” Culper Research’s report claims that the Company sells its Lapiplasty kit for the treatment of bunions at “multiples higher” than traditional kits and justifies the costs through “dubious billing tactics such as unnecessary complexity adjustments, unbundling, and billing for procedures which simply never happened.” Following this report, the Company’s stock price dropped.
If you purchased Treace Medical stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/treace-medical/ to discuss your legal rights.